AlphAIAlphAI — Financial news for AI agents
proactiveinvestors.comAUG 312 min read$BIVI

BioVie completes final patient visit in Phase 2 Long COVID trial

BioVie Inc (BIVI, BIVIW) completed its Phase 2 ADDRESS-LC trial for bezisterim in Long COVID patients, with topline results expected by September 2026. The study evaluates the drug's efficacy in improving neurological symptoms. The trial is fully funded by a U.S. Department of War grant. BioVie aims to address a condition affecting 17-20 million U.S. adults, with no FDA-approved treatments currently available.

Original reporting
proactiveinvestors.com
Published Aug 31, 2026, 2:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 2:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BioVie completes final patient visit in Phase 2 Long COVID trial — source image
Source · proactiveinvestors.com
Decision brief

The 30-second read

$BIVINeutralLow
01

Why it matters

The completion of the final patient visit is a procedural update that signals the trial is on schedule, but price movement will depend on the upcoming data.

02

Market read

Short‑term relevance is modest; the real catalyst will be the September topline results.

03

What to watch

Funding source from the U.S. Department of War may signal strong government backing, but also adds regulatory scrutiny.

Relevance 5/10Novelty 5/10Timing: before September 2026 data release

Background

BioVie is a clinical‑stage biotech focused on neurological disorders; its Long COVID program is funded by a U.S. defense grant.

Company-level read

Ticker impact

$BIVINeutralMedium confidence
Context

BioVie announced completion of the final on‑treatment visit in its Phase 2 Long COVID trial, a new milestone for the drug bezisterim.

Expected impact

Potential modest upside ahead of data release; downside risk if data disappoint.

Evidence & confidence

Biotech stocks often rally on positive trial progress, but the actual catalyst is the upcoming data, not the visit completion itself.

Market effects

Sector

Adds to the pipeline momentum for Long COVID therapeutics, a niche but growing sector.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minor global relevance unless trial data shows breakthrough efficacy.

Counterpoint

What could challenge this read

Investors may wait for actual efficacy data rather than trade on a procedural milestone.

Key entities

  • company
    BioVie Inc

    NASDAQ‑listed biotech developing bezisterim for Long COVID.

  • government
    U.S. Department of War

    Funding source for the trial.

Read at source← All news

Related articles

SEP 16
$BIVIMedAI 8/10

RedChip Companies, Inc.: Join BioVie's Exclusive Live Investor Webinar: Inside the ADDRESS-LC Phase 2 Results

BioVie (NASDAQ:BIVI) will host an investor webinar on September 23, 2026, to discuss Phase 2 results of its drug bezisterim for Long COVID. CEO Cuong Do will present findings showing potential across key symptoms and discuss implications for neurological disorders. The company believes positive results could support bezisterim's development for multiple CNS conditions.

finanznachrichten.de2 min
SEP 15
$BIVIMedAI 8/10

BioVie Phase 2 trial shows bezisterim eases fatigue, cognitive symptoms in severe Long COVID cases

BioVie Inc. reported Phase 2 trial results for bezisterim, showing statistically significant symptom improvements in severe Long COVID patients with high baseline disease burden. The 203-patient trial evaluated 22 clinical outcomes and biomarkers. Subgroup analyses showed significant improvements in fatigue, cognitive impairment, and other symptoms. The company plans further Phase 3 trials to confirm these results. According to the company, bezisterim may become the first therapy for neurologica

proactiveinvestors.com2 min
SEP 15
$BIVIMedAI 8/10

BioVie's Bezisterim Shows Phase 2 Signal In Long COVID; Stock Down

BioVie Inc. (BIVI) reported Phase 2 trial results for Bezisterim, showing significant improvements in Long COVID patients with high baseline fatigue and cognitive impairment. The drug demonstrated advantages over placebo on 21 of 22 endpoints and had a similar safety profile to placebo. BioVie plans to advance to Phase 3 trials. BIVI stock is down 8.23% in pre-market trading.

rttnews.com2 min
SEP 15
$BIVIMedAI 9/10

BioVie, Inc.: BioVie Announces Topline Results from Phase 2 ADDRESS-LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

BioVie Inc. (BIVI) reported positive Phase 2 trial results for bezisterim, showing statistically significant benefits in Long COVID patients with high baseline fatigue, cognitive impairment, and post-exertional malaise. The drug outperformed placebo on 21 of 22 endpoints in these subgroups, with a safety profile similar to placebo. The company plans to discuss the results in a conference call today.

finanznachrichten.de2 min
SEP 8
$BIVIMed

BioVie advances Parkinson’s Phase 3 development program with FDA engagement

BioVie Inc. (BIVI, BIVIW) announced plans to advance its Phase 3 trial for bezisterim in Parkinson’s disease, with an End-of-Phase 2 meeting requested with the FDA. The trial will focus on motor symptoms (MDS-UPDRS Part III) as the primary endpoint, with non-motor symptoms (MDS-UPDRS Part I) as a co-primary or secondary endpoint. Phase 2 results suggested greater benefits for patients with higher inflammation levels. The company expects to discuss the trial design with the FDA later this year an

proactiveinvestors.com2 min